PRIVA-PERINDOPRIL ERBUMINE TABLET

Pajjiż: Kanada

Lingwa: Ingliż

Sors: Health Canada

Ingredjent attiv:

PERINDOPRIL ERBUMINE

Disponibbli minn:

NORA PHARMA INC

Kodiċi ATC:

C09AA04

INN (Isem Internazzjonali):

PERINDOPRIL

Dożaġġ:

2MG

Għamla farmaċewtika:

TABLET

Kompożizzjoni:

PERINDOPRIL ERBUMINE 2MG

Rotta amministrattiva:

ORAL

Unitajiet fil-pakkett:

100

Tip ta 'preskrizzjoni:

Prescription

Żona terapewtika:

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

Sommarju tal-prodott:

Active ingredient group (AIG) number: 0127178001; AHFS:

L-istatus ta 'awtorizzazzjoni:

CANCELLED POST MARKET

Data ta 'l-awtorizzazzjoni:

2022-07-25

Karatteristiċi tal-prodott

_Priva-PERINDOPRIL ERBUMINE _
_Page 1 of 55 _
PRODUCT MONOGRAPH
PR PRIVA-PERINDOPRIL ERBUMINE
PERINDOPRIL ERBUMINE TABLETS, USP
2 MG, 4 MG AND 8 MG ANGIOTENSIN CONVERTING ENZYME INHIBITOR
NORA PHARMA INC.
1565, Lionel-Boulet Boul.
Varennes, Québec
J3X 1P7
CONTROL NUMBER: 264075
DATE OF PREPARATION:
May 31, 2022
_Priva-PERINDOPRIL ERBUMINE _
_Page 2 of 55 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION ............................................................. 3
SUMMARY PRODUCT INFORMATION
.............................................................................
3
INDICATIONS AND CLINICAL USE
..................................................................................
3
CONTRAINDICATIONS
........................................................................................................
4
WARNINGS AND PRECAUTIONS
......................................................................................
5
ADVERSE REACTIONS
......................................................................................................
13
DRUG INTERACTIONS
......................................................................................................
20
DOSAGE AND ADMINISTRATION
..................................................................................
22
OVERDOSAGE
.....................................................................................................................
24
ACTION AND CLINICAL PHARMACOLOGY
................................................................. 25
STORAGE AND STABILITY
..............................................................................................
28
SPECIAL HANDLING INSTRUCTIONS
............................................................................
28
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................. 29
PART II: SCIENTIFIC INFORMATION ...................................................................................
30
PHARMACEUTICAL INFORMATION
.........................................